A covalently stabilized lipid-Polycation-DNA (sLPD) vector for antisense oligonucleotide delivery

Molecular Pharmaceutics

Volumn 8, Issue 3, 2011, Pages 709-715

  Yang, Xiaojuan ^a   Peng, Yong ^b,c   Yu, Bo ^a,d   Yu, Jianhua ^b   Zhou, Chenguang ^a   Mao, Yicheng ^a   Lee, L James ^a,d   Lee, Robert J ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b The Ohio State University   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

antisense oligonucleotide; cancer; drug delivery; immunotherapy; nanoparticles; reversible cross linking

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; 11 HEXADECENAL; CHOLESTEROL; DEXTRO ALPHA TOCOPHEROL POLYETHYLENE GLYCOL SUCCINATE; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; LINOLEIC ACID; LIPID; OBLIMERSEN; POLYCATION; POLYETHYLENEIMINE; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; COVALENT BOND; CYTOKINE PRODUCTION; DNA VECTOR; DOWN REGULATION; DRUG EFFECT; DRUG STABILITY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CYTOKINES; DNA; FEMALE; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LIPIDS; MICE; MICE, NUDE; OLIGONUCLEOTIDES, ANTISENSE; POLYAMINES;

EID: 79958270327     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100272k     Document Type: Article

References (35)

1. Crooke, S. T. Progress in antisense technology Annu. Rev. Med. 2004, 55, 61-95 (Pubitemid 38316716)
2. Zhang, C.; Pei, J.; Kumar, D.; Sakabe, I.; Boudreau, H. E.; Gokhale, P. C.; Kasid, U. N. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles Methods Mol. Biol. 2007, 361, 163-185 (Pubitemid 350183206)
3. Shoji, Y.; Nakashima, H. Current status of delivery systems to improve target efficacy of oligonucleotides Curr. Pharm. Des. 2004, 10, 785-796 (Pubitemid 38292406)
4. Wheeler, J. J.; Palmer, L.; Ossanlou, M.; MacLachlan, I.; Graham, R. W.; Zhang, Y. P.; Hope, M. J.; Scherrer, P.; Cullis, P. R. Stabilized plasmid-lipid particles: construction and characterization Gene Ther. 1999, 6, 271-281 (Pubitemid 29089926)
5. Zaghloul, E. M.; Viola, J. R.; Zuber, G.; Smith, C. I.; Lundin, K. E. Formulation and delivery of splice-correction antisense oligonucleotides by amino acid modified polyethylenimine Mol. Pharmaceutics 2010, 7, 652-663
6. Junghans, M.; Kreuter, J.; Zimmer, A. Antisense delivery using protamine-oligonucleotide particles Nucleic Acids Res. 2000, 28, E45
7. Gao, X.; Huang, L. Potentiation of cationic liposome-mediated gene delivery by polycations Biochemistry 1996, 35, 1027-1036 (Pubitemid 26034590)
8. Yang, X.; Koh, C. G.; Liu, S.; Pan, X.; Santhanam, R.; Yu, B.; Peng, Y.; Pang, J.; Golan, S.; Talmon, Y.; Jin, Y.; Muthusamy, N.; Byrd, J. C.; Chan, K. K.; Lee, L. J.; Marcucci, G.; Lee, R. J. Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2 Mol. Pharmaceutics 2009, 6, 221-230
9. Li, S.; Huang, L. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes Gene Ther. 1997, 4, 891-900 (Pubitemid 27437714)
10. Junghans, M.; Loitsch, S. M.; Steiniger, S. C.; Kreuter, J.; Zimmer, A. Cationic lipid-protamine-DNA (LPD) complexes for delivery of antisense c-myc oligonucleotides Eur. J. Pharm. Biopharm. 2005, 60, 287-294 (Pubitemid 40804568)
11. Klasa, R. J.; Gillum, A. M.; Klem, R. E.; Frankel, S. R. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment Antisense Nucleic Acid Drug Dev. 2002, 12, 193-213 (Pubitemid 34815931)
12. Marcucci, G.; Stock, W.; Dai, G.; Klisovic, R. B.; Liu, S.; Klisovic, M. I.; Blum, W.; Kefauver, C.; Sher, D. A.; Green, M.; Moran, M.; Maharry, K.; Novick, S.; Bloomfield, C. D.; Zwiebel, J. A.; Larson, R. A.; Grever, M. R.; Chan, K. K.; Byrd, J. C. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity J. Clin. Oncol. 2005, 23, 3404-3411
13. Jeffs, L. B.; Palmer, L. R.; Ambegia, E. G.; Giesbrecht, C.; Ewanick, S.; MacLachlan, I. A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA Pharm. Res. 2005, 22, 362-372 (Pubitemid 40558494)
14. Zhang, X.; Koh, C. G.; Yu, B.; Liu, S.; Piao, L.; Marcucci, G.; Lee, R. J.; Lee, L. J. Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide g3139 in a murine k562 xenograft model Pharm. Res. 2009, 26, 1516-1524
15. Pan, X.; Chen, L.; Liu, S.; Yang, X.; Gao, J. X.; Lee, R. J. Antitumor activity of G3139 lipid nanoparticles (LNPs) Mol. Pharmaceutics 2009, 6, 211-220
16. Ogihara-Umeda, I.; Kojima, S. Cholesterol enhances the delivery of liposome-encapsulated gallium-67 to tumors Eur. J. Nucl. Med. 1989, 15, 612-617 (Pubitemid 19236005)
17. Somavarapu, S.; Pandit, S.; Gradassi, G.; Bandera, M.; Ravichandran, E.; Alpar, O. H. Effect of Vitamin E TPGS on immune response to nasally delivered diphtheria toxoid loaded poly(caprolactone) microparticles Int. J. Pharm. 2005, 298, 344-347 (Pubitemid 40910740)
18. Feng, S. S.; Huang, G. F. Effects of emulsifiers on the controlled release of paclitaxel (Taxol (R)) from nanospheres of biodegradable polymers J. Controlled Release 2001, 71, 53-69
19. Mu, L.; Feng, S. S. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol (R)) J. Controlled Release 2002, 80, 129-144 (Pubitemid 34273754)
20. Shigeta, Y.; Imanaka, H.; Ando, H.; Ryu, A.; Oku, N.; Baba, N.; Makino, T. Skin whitening effect of linoleic acid is enhanced by liposomal formulations Biol. Pharm. Bull. 2004, 27, 591-594 (Pubitemid 41701853)
21. Orrantia, E.; Chang, P. L. Intracellular distribution of DNA internalized through calcium phosphate precipitation Exp. Cell Res. 1990, 190 (2) 170-174
22. Batard, P.; Jordan, M.; Wurm, F. Transfer of high copy number plasmid into mammalian cells by calcium phosphate transfection Gene 2001, 270, 61-68 (Pubitemid 32525802)
23. Roy, I.; Mitra, S.; Maitra, A.; Mozumdar, S. Calcium phosphate nanoparticles as novel non-viral vectors for targeted gene delivery Int. J. Pharm. 2003, 250, 25-33 (Pubitemid 35447934)
24. Bisht, S.; Bhakta, G.; Mitra, S.; Maitra, A. pDNA loaded calcium phosphate nanoparticles: highly efficient non-viral vector for gene delivery Int. J. Pharm. 2005, 288, 157-168 (Pubitemid 39656464)
25. Li, J.; Chen, Y. C.; Tseng, Y. C.; Mozumdar, S.; Huang, L. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery J. Controlled Release 2010, 142, 416-421
26. Zhou, C.; Yu, B.; Yang, X.; Huo, T.; Lee, L. J.; Barth, R. F.; Lee, R. J. Lipid-coated nano-calcium-phosphate (LNCP) for gene delivery Int. J. Pharm. 2010, 392, 201-208
27. Dai, G.; Chan, K. K.; Liu, S.; Hoyt, D.; Whitman, S.; Klisovic, M.; Shen, T.; Caligiuri, M. A.; Byrd, J.; Grever, M.; Marcucci, G. Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia Clin. Cancer Res. 2005, 11 (8) 2998-3008 (Pubitemid 40525205)
28. Moore, J.; Seiter, K.; Kolitz, J.; Stock, W.; Giles, F.; Kalaycio, M.; Zenk, D.; Marcucci, G. A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse Leuk. Res. 2006, 30, 777-783 (Pubitemid 43816693)
29. Gekeler, V.; Gimmnich, P.; Hofmann, H. P.; Grebe, C.; Römmele, M.; Leja, A.; Baudler, M.; Benimetskaya, L.; Gonser, B.; Pieles, U.; Maier, T.; Wagner, T.; Sanders, K.; Beck, J. F.; Hanauer, G.; Stein, C. A. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice Oligonucleotides 2006, 16 (1) 83-93
30. Krieg, A. M. CpG motifs in bacterial DNA and their immune effects Annu. Rev. Immunol. 2002, 20, 709-760 (Pubitemid 34293438)
31. Dow, S. W.; Fradkin, L. G.; Liggitt, D. H.; Willson, A. P.; Heath, T. D.; Potter, T. A. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously J. Immunol. 1999, 163 (3) 1552-1561 (Pubitemid 29352779)
32. Mui, B.; Raney, S. G.; Semple, S. C.; Hope, M. J. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles J. Pharmacol. Exp. Ther. 2001, 298 (3) 1185-1192 (Pubitemid 32761938)
33. Gursel, I.; Gursel, M.; Ishii, K. J.; Klinman, D. M. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides J. Immunol. 2001, 167 (6) 3324-3328 (Pubitemid 32852574)
34. Cui, Z.; Han, S. J.; Vangasseri, D. P.; Huang, L. Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier Mol. Pharmaceutics 2005, 2 (1) 22-28 (Pubitemid 40314726)
35. Dobrovolskaia, M. A.; McNeil, S. E. Immunological properties of engineered nanomaterials Nat. Nanotechnol. 2007, 2 (8) 469-478 (Pubitemid 47220069)